TCR2 Therapeutics was founded in 2015 by Dr. Patrick Baeuerle and MPM Capital with the vision of developing a novel T cell therapy approach that overcomes the challenges and limitations of current oncology treatments including CAR-T and engineered T cell receptor (TCR) therapies.
Our TRuC™ platform is unique in recruiting the entire T cell receptor without HLA matching allowing us to address the broadest population of patients with hematological malignancies and solid tumors. We have demonstrated better efficacy, persistence and safety than alternative approaches in preclinical models.
We have multiple TRuC™ formats and multiple programs. The company’s lead program TC-210 has been designed to target mesothelin-positive solid tumors and is expected to enter the clinic in 2018.
TCR2 is headquartered in the heart of Kendall Square in Cambridge, MA. The company raised a $44.5M Series A financing in October 2015 and an oversubscribed Series B financing of $125M in March 2018.